WO2000004835A1 - Apparatus for lowering intra-abdominal pressure - Google Patents
Apparatus for lowering intra-abdominal pressure Download PDFInfo
- Publication number
- WO2000004835A1 WO2000004835A1 PCT/US1999/016173 US9916173W WO0004835A1 WO 2000004835 A1 WO2000004835 A1 WO 2000004835A1 US 9916173 W US9916173 W US 9916173W WO 0004835 A1 WO0004835 A1 WO 0004835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pressure
- patient
- abdominal
- negative pressure
- intra
- Prior art date
Links
- 230000003187 abdominal effect Effects 0.000 claims abstract description 82
- 230000006837 decompression Effects 0.000 claims abstract description 66
- 210000001015 abdomen Anatomy 0.000 claims abstract description 35
- 230000007246 mechanism Effects 0.000 claims abstract description 15
- 230000033001 locomotion Effects 0.000 claims abstract description 6
- 210000003932 urinary bladder Anatomy 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 16
- 238000011282 treatment Methods 0.000 abstract description 27
- 230000007423 decrease Effects 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 12
- 230000036407 pain Effects 0.000 abstract description 12
- 238000005259 measurement Methods 0.000 abstract description 8
- 210000000038 chest Anatomy 0.000 description 26
- 208000008589 Obesity Diseases 0.000 description 14
- 239000003570 air Substances 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 13
- 206010020772 Hypertension Diseases 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 10
- 238000009530 blood pressure measurement Methods 0.000 description 10
- 208000037805 labour Diseases 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000007917 intracranial administration Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 7
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 7
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 7
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 7
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 7
- 229960002478 aldosterone Drugs 0.000 description 7
- 208000001381 pseudotumor cerebri Diseases 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 201000002282 venous insufficiency Diseases 0.000 description 7
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 6
- 206010021133 Hypoventilation Diseases 0.000 description 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 6
- 210000004197 pelvis Anatomy 0.000 description 6
- 201000011461 pre-eclampsia Diseases 0.000 description 6
- 208000037905 systemic hypertension Diseases 0.000 description 6
- 208000004611 Abdominal Obesity Diseases 0.000 description 5
- 206010065941 Central obesity Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 206010004053 Bacterial toxaemia Diseases 0.000 description 4
- 208000028399 Critical Illness Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000013222 Toxemia Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000003788 cerebral perfusion Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010021620 Incisional hernias Diseases 0.000 description 3
- 208000007914 Labor Pain Diseases 0.000 description 3
- 208000035945 Labour pain Diseases 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000004578 fetal growth Effects 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000001022 morbid obesity Diseases 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000012175 toxemia of pregnancy Diseases 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- PGOOBECODWQEAB-UHFFFAOYSA-N (E)-clothianidin Chemical compound [O-][N+](=O)\N=C(/NC)NCC1=CN=C(Cl)S1 PGOOBECODWQEAB-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010051290 Central nervous system lesion Diseases 0.000 description 2
- 208000032943 Fetal Distress Diseases 0.000 description 2
- 206010016855 Foetal distress syndrome Diseases 0.000 description 2
- 206010022773 Intracranial pressure increased Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 201000009941 intracranial hypertension Diseases 0.000 description 2
- 230000009593 intrauterine fetal growth Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 210000003049 pelvic bone Anatomy 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000005608 severe pre-eclampsia Diseases 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010019707 Hepatic rupture Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010067508 Low birth weight baby Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 206010035004 Pickwickian syndrome Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046797 Uterine ischaemia Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000012730 cephalometry Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 229920001821 foam rubber Polymers 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/005—Pneumatic massage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/08—Trunk
- A61H2205/083—Abdomen
Definitions
- the invention is generally related to medical devices used for lowering intra-abdominal pressure (IAP)in patients. More particularly, the invention pertains to a device which is more comfortable to the patient and which reduces or eliminates pain on the lower rib cage of the patient.
- IAP intra-abdominal pressure
- the device was used in 100 primiparas and 42 multiparas in the first study and 302 primiparas and 188 multiparas in the second study, and there was an 86% excellent or good pain relief response with its use.
- the device was modified with a switch to the vacuum pump which the patient activated at the onset of labor pain and turned off at the completion of a contraction. This device was manufactured by the J. H. Emerson Co., Cambridge, Mass., and called the
- the mean fetal growth rate of the decompression group was significantly greater than the untreated group and was associated with a significantly higher estrogen excretion and lower incidence of fetal distress as well as a significantly higher Apgar score and a lower percent of low birth weight babies and perinatal mortality.
- Gynaecol. 97:467-469, 1990, suggests that the negative reaction to the failure of abdominal decompression to improve fetal development scores or intelligence quotients in normal pregnancies, as initially suggested by Heyns, may detract from its possible benefits to decrease the pain of labor and fetal distress, or treat toxemia or poor fetal growth which may be secondary to impaired placental blood flow. Shimonovitz et al., Er . J . Obstet . Gynaecol . ,
- relatively low levels of negative pressure e.g., -20 to -45 mm Hg
- a patient's intra- abdominal pressure is advantageously lowered by providing abdominal decompression to the patient on a continuous basis for an extended period of time.
- the abdominal decompression device can be constructed in a variety of forms with the principal object being to apply negative pressure at the site of the patient's chest and abdomen.
- the abdominal decompression device will preferably either have an air tight suit positioned over a rigid frame which is spaced approximately 4-6 inches away from the patient's chest and abdomen; or, alternatively, will include a rigid dome vest made of plastic or other suitable materials which will be held in place on the patient's chest and abdomen.
- a material which traverses around the patient's back that is connected using clips or hook and loop connecters (Velcro®) or other suitable connectors can be used to hold the dome in place, or it may be self-sealing when a vacuum is applied.
- a pump is connected to the air tight suit or dome vest and is used to apply negative pressure in the space between the suit or vest and the patient.
- a gauge is connected to the line connected to the pump for aiding in regulating the vacuum pressure inside the abdominal decompression device.
- the method and apparatus of this invention is directed to providing a low vacuum pressure (e.g., 20-45 mm Hg) which can be tolerated by a patient for an extended period of time.
- a low vacuum pressure e.g. 20-45 mm Hg
- the abdominal decompression device will be worn for six to twelve hours, and most preferably overnight for eight hours while the patient is sleeping.
- the method and apparatus of this invention contemplates the application of continuous, as opposed to intermittent, negative pressure on the patient's chest and abdomen.
- the prolonged, continuous, low negative pressure treatment provides a more reliable mechanism for reducing intra-abdominal pressure than prior devices which rely on high pressures for intermittent time periods.
- the method and apparatus of this invention contemplate using the patient's urinary bladder pressure as an assessment of intra-abdominal pressure. It has been found that in most clinical situations urinary bladder pressure accurately reflects intra- abdominal pressure.
- the urinary bladder pressure measurement can be determined using a Foley catheter or other suitable device, and would preferably be left in place during the initial application of vacuum pressure to the patient's chest and abdomen.
- an important feature of this invention is to provide a mechanism which will counteract the inward pulling forces during application of negative pressure inside the compartment, but which will still permit a tight seal over the patient's chest allowing the negative pressure to act primarily to pull the patient's abdomen upwards.
- progressively increasing levels of force can be applied to counteract progressively increasing amounts of inward pulling forces exerted during application of vacuum pressure within the compartment.
- a pulley mechanism is connected to the compartment, and allows the application of increasing amounts of weight thereto for countering the inward pulling forces exerted during application of vacuum pressure within the compartment. Countering the inward pulling forces during application of negative pressure reduces or eliminates pressure pain on the lower rib cage and pelvic bones, and produces further decreases in urinary bladder pressure.
- Figures 2a and 2b show side and top schematic views of a domed vest for abdominal decompression according to the present invention.
- Figures 3a and 3b show schematic views of a counter-traction mechanism for countering the inward pulling forces exerted during application of negative pressure within the domed vest wherein the configuration of Figure 3a is used when the patient is lying on his or her back and the configuration of Figure 3b is used when the patient is lying on his her side.
- IAP intra-abdominal pressure
- IAP also pushes the diaphragm cephalad, "squeezing" the lungs, interfering with respiratory function, and raising intra-thoracic pressure. This impairs venous return from the brain, raising intracranial pressure, as well as impairs return from the liver, interfering with the intestinal venous drainage and causing liver vascular engorgement, leading to the risk of hepatic rupture in the case of eclampsia. Lowering IAP can be useful for the treatment of pre-eclampsia and toxemia of pregnancy, decreasing the pain of labor, and improving intra- uterine fetal growth. However, for more effective treatment than has been achieved with previous investigative devices, a more gradual decrease in negative pressure is required.
- the method and apparatus of this invention can be used for treating a number of different conditions.
- increased IAP in severely obese individuals can result in obesity hypoventilation syndrome, obesity related diabetes as well as gestational diabetes, chronic venous stasis ulcers or edema (e.g., lower extremity), idiopathic intracranial hypertension (pseudotumor cerebri) , systemic hypertension secondary to obesity, nephrotic syndrome of obesity, and gastro- esophageal reflux.
- is often seen in critically ill medical or surgical patients where there is an acute increase in IAP, and this syndrome may cause kidney and lung failure, infarction of the intestine, or marked increases in brain cerebrospinal fluid pressure. Patients suffering from acute abdominal compartment syndrome should benefit from applying a negative pressure continuously in the intensive care unit or other treatment setting for as long as the IAP is elevated.
- Patients with head injuries or cerebral space occupying lesions can be treated by lowering intra- abdominal pressure using the method and apparatus of this invention.
- Lowering intra-abdominal pressure lowers intrapleural pressure, thus improving venous draining and ultimately lowering intracranial pressure.
- By lowering the intracranial pressure the patient's condition will be improved.
- the method and apparatus of this invention may also be useful in the treatment of obesity related Type II diabetes mellitus and sleep apnea syndrome.
- the urinary bladder pressure is utilized to estimate and monitor changes in IAP. It has been found that urinary bladder pressure measurements accurately reflect IAP in most clinical situations. Studies have shown that the average urinary bladder pressure in morbidly obese patients is 18 ⁇ 0.7 (range 12 to 42) cm H 2 0, while non-obese patients have a urinary bladder pressure of 7.1 ⁇ 1.6 cm H 2 0. In addition, clinical studies have shown that the urinary bladder pressure is between 20-30 cm H 2 0 during the third trimester of pregnancy. The apparatus of this invention would be used to apply negative pressure on the patient's abdomen until such time as the urinary bladder pressure measurements are more closely associated with those found in non-obese patients (e.g., 10-14 cm H 2 0) .
- the target urinary bladder pressure measurement would be selectable by the physician, and would be chosen to be clinically effective for the condition or syndrome being treated.
- bladder pressure measurements of the patient under treatment to control the intensity and duration of treatment with the negative pressure device, the IAP of the patient can be continuously monitored during treatment without the need for intermittent breaks in negative pressure to evaluate IAP by other means.
- Figures la and lb schematically show one example of an abdominal decompression system according to the present invention.
- Inflatable cuffs 10 and 12 are secured at the chest and pelvis of the patient being treated. Cuffs 10 and 12 are intended to maintain an air tight enclosure; therefore, body contacting surfaces may be provided with features intended to promote air tight connections.
- silicone oil may be applied and held within recessed regions (not shown) on the body contacting surfaces of the cuffs 10 and 12, or the body contacting surfaces of the cuffs 10 and 12 could include pocket regions designed to prevent ambient air from being suctioned under the cuffs 10 and 12.
- the preferred abdominal decompression device utilizes inflatable cuffs 10 and 12 because of the advantages of being lightweight and conformable to the contours of the patient's body, other materials such as neoprene rubber or the like might be used for the cuffs 10 and 12.
- a drawstring can by used to cinch the material around the patient's chest and pelvis.
- Figures la-b show a cuff 12 placed at the pelvis
- the abdominal decompression device could be "sack- shaped", including only one cuff 10 positioned at the patient's chest and extending therefrom to cover the wearer's legs.
- An air tight enclosure 14 is positioned between cuffs 10 and 12.
- the air tight enclosure 14 can be made of plastic, nylon®, goretex®, or other suitable materials. In the case of a single cuff 10 design, the air tight enclosure 14 would extend over the patient's legs and feet.
- An air tight zipper 16 could be provided for easier patient access into the abdominal decompression device.
- a non-zippered overlap enclosure could be provided which self-seals with the application of negative pressure.
- a frame with multiple perforations 18, preferably made of metal, plastic, or other rigid materials is positioned under the air tight enclosure 14 and is used to support the air tight enclosure slightly above the patient's chest and abdomen, but sufficient to provide access for the application of negative pressure.
- a preferred distance for the frame 18 to hold the enclosure 14 above the patient's chest and abdomen is two to six inches.
- the frame 18 may advantageously encircle three quarters of the patient's body and be positioned on the mattress of a bed or be affixed to a back support 20 on which the patient rests during treatment.
- the back support can be made from any suitable material and should provide the patient with comfort during extended periods of wear either in bed or in a chair.
- Negative pressure is applied in the space between the frame 18 and the abdomen using a vacuum source 22.
- the air tight enclosure 14 on top of the frame 18 allows the negative pressure environment around the patient's chest and abdomen to be generated by the vacuum source 22.
- the vacuum source could be a variable vacuum pump, an AC pump or a DC pump, or any other suitable device which can evacuate air from between the frame 18 and patient's chest and abdomen
- a pressure gauge 24 is provided to monitor the negative pressure being applied.
- a constant negative pressure of approximately -20 to -45 mm Hg is exerted by vacuum source 22, and the pressure is applied continuously for an extended treatment period. In most cases, it is anticipated that the treatment period will be six to twelve hours (e.g., approximately eight hours overnight) ; however, it should be understood for certain conditions longer or shorter periods might be more clinically appropriate.
- the amount of negative pressure is ideally low
- Figures 2a and 2b show an alternative design for the abdominal decompression device according to the present invention.
- a rigid dome 30 is placed over the patient's chest and abdomen.
- the dome 30 extends above the patient and defines a cavity which can be used to apply negative pressure to the patient's chest and abdomen. Vacuum pressure is applied to the cavity through port 32.
- the dome 30 can be made of a plastic, fiberglass, metal or other suitable materials, and should be of sufficient rigidity to withstand deforming under the pressure of the applied vacuum (e.g., preferably 20 to -45 mmHg as discussed above in connection with Figures la and lb).
- An air tight seal 34 such as a foam rubber gasket or other suitable material, will seal the dome 30 against the patient's chest and abdomen.
- the dome 30 will be held in place using either an attached posterior vest 36 or by straps which extend from one side of the dome 30 around the patient's back and is connected to the opposite side of the dome 30 using connectors 38 and 40 which may be Velcro® strips, clips tape, straps with punch holes for connection to a belt-type connector, or other suitable devices.
- the shell may fit in a way to "self- seal" so that straps are not required.
- the abdominal decompression device of Figures 2a and 2b has the advantage of enabling the patient to get in and out of the device more easily than the design shown in Figures la and lb.
- the shell of the intra- abdominal pressure device is preferably designed to be 10 to 20 cm above the patient's abdomen so that, should an excessive negative pressure be applied, intentionally or by accident, the abdominal wall cannot be raised further and, therefore, there cannot be an excessive reduction in intra-abdominal pressure which could lead to serious cardiovascular complications.
- the device has a self- protective mechanism which obviates the need for an automatic "shut-off switch" on the negative pressure pump.
- the shell is restricted by the chest component (i.e., it is designed to be applied below the breasts) and the pubic bone, it is also prevented from migrating toward the back, so that the space above the abdomen remains fixed.
- Urinary bladder pressure detection system shown as element 26 in Figures la-b and element 26' in Figures 2a-b, provides measurements of the patient's urinary bladder pressure.
- the detection system 26 or 26' can take the form of a urinary Foley catheter or another suitable device.
- the patient's urinary bladder pressure accurately reflects the intra-abdominal pressure of the patient being treated.
- the normal bladder pressure in non-obese individuals averages approximately 7 cm H 2 0, whereas the bladder pressure is considerably elevated (e.g., 15-42 cm H 2 0) in severely obese patients, in patients suffering from acute abdominal compartment syndrome, and in patients with complicated pregnancies.
- the bladder pressure measurement should provide an effective mechanism for controlling the treatment regimen of a patient suffering from elevated IAP in a number of different situations.
- the abdominal decompression device can be fitted onto the patient and the duration of the negative pressure and amount of negative pressure applied can be controlled in a manner which achieves a preselected level of bladder pressure. That is, treatment continues until halted by a physician or the pre-selected level is reached.
- a computer controller (not shown) could be affixed to the bladder pressure detection system 26 or 26' and vacuum source 22 to control the amount of vacuum in the compartment enclosed based on bladder measurements. This would allow automatic adjustment of vacuum pressure in accordance with changes in bladder pressure measurement and automatic cut-off when desired target levels are reached.
- a pre-selected time of negative pressure application can be used, with the bladder pressure measurements providing feedback on the effectiveness of the treatment.
- Figures 3a-b show a test counter-traction system which has been successfully used in clinical experiments.
- the shell 50 which fits over the patient's abdomen and operates in the same way as dome 30 in Figures 2a-b or covered frame 18 in Figures la-b, is fitted with a vacuum hose 52 which allows drawing a vacuum in the space between the inside of the shell 50 and the patient's body.
- a wire 54 is secured to the shell 50 by an anchor 56.
- the wire 54 extends to a spring-tension scale 58 which is connected to a pulley 60.
- the pulley 60 is positioned on a wire 62 positioned in a frame 64 cantileavered over the patient.
- the end of wire 62 is connected to a hanging platform 66 on which weights 68 can be positioned.
- weights 68 are placed on platform 66, and this exerts a force which pulls upward on shell 50.
- Weights 68 are preferably added in progressively increasing amounts until the maximum negative pressure in the space between the inside of the shell 50 and the patient's abdomen is reached without loss of the vacuum connection with the patient. In experiments to date, up to 18 Kg of negative counter-traction has been used as measured with the spring-tension scale 58.
- Figure 3b shows a particular advantage of the countertraction pulley mechanism in that it permits a person to lay on his or her side during use of the shell 50. This is accomplished by positioning wire 54 under a pulley 70 positioned on the upright portion of frame 64. In this configuration, the wire 54 is exerting a force directly away from the shell's 50 surface when the patient is laying on his or her side facing the frame 64.
- the ability to treat a patient laying flat or on his or her side can help alleviate patient discomfort, bed sores, pressure ulcers, and other clinical problems .
- Pigs weighing approximately 70 kg have been studied using an abdominal decompression device similar to that shown in Figures la-b, which has been named an ⁇ gABSHELI
- a polyethylene glycol solution Go-Lytely
- IAP intra-abdominal pressure
- the normal fall in cardiac index associated with this increase in IAP was prevented by increasing the intra-vascular volume with Lactated Ringer's solution, in an attempt to mimic a chronic, compensated state of increased IAP as seen in both severe obesity and pre-eclampsia.
- the increased IAP and volume expansion was associated with a significant (p ⁇ 0.01) increase in mean systemic arterial pressure, from 91 ⁇ 4 to 126 ⁇ 3 mm Hg.
- Application of the ABSHELL device at a pressure of -40 mm Hg for four hours was associated with a 12 mm Hg decrease (p ⁇ 0.01) in IAP and fall (p ⁇ 0.01) in mean systemic arterial pressure to 101 ⁇ 23 mm Hg.
- the increased IAP was also associated with an increase (P ⁇ 0.01) in intracranial pressure from 11 ⁇ 0.8 to 21 ⁇ 1.9 mm Hg; this decreased (p ⁇ 0.01) to 15 + 0.8 mm Hg following application of the
- ABSHELL significant increases in central venous and femoral venous pressures were also noted with the increased IAP which also fell significantly with the use of the ABSHELL. The effects of the ABSHELL were noted immediately after it was turned on and remained effective throughout the four hour period of its application
- IAP intra-abdominal pressure
- BMI body mass index
- SAD sagittal abdominal diameter
- w:h waist:hip
- UBP urinary bladder pressure
- AD Abdominal decompression
- PRA Plasma renin activity
- ALDO aldosterone
- IAP intra- abdominal pressure
- Additional IAP related problems in obesity might include pseudotumor cerebri, obesity hypoventilation, gastroesophageal reflux disease, lower extremity venous stasis, and incisional hernia. It was hypothesized that the externally applied abdominal continuous negative pressure device (ABSHELL) of this invention could reverse this pathophysiology.
- ABSHELL abdominal continuous negative pressure device
- Urinary Bladder Pressure UBP
- mean systemic arterial pressure SAP
- central venous pressure CVP
- pulminary capillary wedge pressure PCWP
- cardiac index CI
- ITVx-sect internal jugular vein cross- section diameter
- IJW velocity
- this patient's subcutaneous tissue measured 12 cm; whereas, the patients who responded had subcutaneous tissue measurements of 6-9 cm.
- the patient whose bladder pressure failed to respond had a much heavier abdominal wall which would have required a stronger vacuum pump to lower this pressure.
- ABSHELL through the night (e.g., approximately eight hours) would result in a significant decrease in intra-vascular volume which would lead to a decrease in systemic as well as pulmonary artery blood pressures. It should also improve arterial blood gases, as a reflection of improved pulmonary function.
- intra-abdominal pressure was increased by incrementally inflating the balloon and parameters were re-measured thirty minutes after each increase.
- the ABSHELL was modified with a counter-traction mechanism shown in Figures 3a-b to alleviate pressure pain on the patient's rib cage and pelvis.
- Two patients have been studied in the modified device. The pain previously noted with the ABSHELL was not present in either patient.
- the counter-traction mechanism provided an additional decrease in IAP (as determined by urinary bladder pressure measurements) .
- urinary bladder pressurements decreased to 8-12 cm H 2 0 pressure. This was associated with a decrease in cerebrospinal fluid pressure in one patient with pseudotumor cerebri, and blood pressure in one patient with systemic hypertension.
- ABSHELL will lead to decreased intra-abdominal and pleural pressures, a decrease in intra-vascular volume, decreased systemic and pulmonary blood pressures, improved pulmonary function, decreased lower extremity venous stasis, and decreased intracranial hypertension in morbidly obese patients.
- the ABSHELL device should be of benefit to women with preeclampsia, pregnant women with small growth for gestational age babies, critically ill patients with increased intra- abdominal pressure as a result of an acute abdominal compartment syndrome, and patients with a head injury or space occupying brain lesion.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002335013A CA2335013A1 (en) | 1998-07-24 | 1999-07-16 | Apparatus for lowering intra-abdominal pressure |
JP2000560830A JP2002521083A (en) | 1998-07-24 | 1999-07-16 | Intraperitoneal pressure reducing device |
AU52152/99A AU746731B2 (en) | 1998-07-24 | 1999-07-16 | Apparatus for lowering intra-abdominal pressure |
EP99937283A EP1100388A1 (en) | 1998-07-24 | 1999-07-16 | Apparatus for lowering intra-abdominal pressure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/121,600 | 1998-07-24 | ||
US09/121,600 US5938626A (en) | 1998-07-24 | 1998-07-24 | Apparatus for lowering intra-abdominal pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000004835A1 true WO2000004835A1 (en) | 2000-02-03 |
Family
ID=22397705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/016173 WO2000004835A1 (en) | 1998-07-24 | 1999-07-16 | Apparatus for lowering intra-abdominal pressure |
Country Status (6)
Country | Link |
---|---|
US (1) | US5938626A (en) |
EP (1) | EP1100388A1 (en) |
JP (1) | JP2002521083A (en) |
AU (1) | AU746731B2 (en) |
CA (1) | CA2335013A1 (en) |
WO (1) | WO2000004835A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2680006C1 (en) * | 2018-01-22 | 2019-02-14 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Method for predicting the risk of development of internal hypertension among cardiac surgery patients |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10001845C2 (en) * | 2000-01-18 | 2002-03-07 | Norbert Egger | Fitness device in the form of an item of clothing |
GB0011202D0 (en) | 2000-05-09 | 2000-06-28 | Kci Licensing Inc | Abdominal wound dressing |
US6673099B2 (en) * | 2000-06-09 | 2004-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for prevention of hypothermia in a mammal during prolonged exposure to extreme cold |
KR100463753B1 (en) * | 2000-07-13 | 2004-12-29 | 주식회사 영도의기 | Device for helping delivery |
US6632180B1 (en) * | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
US6595926B1 (en) * | 2000-09-07 | 2003-07-22 | John H. Laragh | Method for evaluating and treating hypertension |
DE10149418A1 (en) * | 2001-10-02 | 2003-04-17 | Norbert Egger | Fitness equipment for aiding slimming comprises a clothing item with independent zones with which alternating positive and negative pressures are applied to body areas being treated |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
US7585281B2 (en) * | 2002-09-10 | 2009-09-08 | Aragon Surgical, Inc. | Vacuum-actuated tissue perforation device for establishing pneumoperitoneum |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
GB0318935D0 (en) * | 2003-08-13 | 2003-09-17 | Mossanen Shams Iden | Pulmonary evaluation device |
GB0325126D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with heat |
GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
US7128735B2 (en) * | 2004-01-02 | 2006-10-31 | Richard Scott Weston | Reduced pressure wound treatment appliance |
US7297141B2 (en) * | 2004-01-20 | 2007-11-20 | Ethicon Endo-Surgery, Inc. | Method for accessing an operative space |
US7585290B2 (en) * | 2004-01-20 | 2009-09-08 | Ethicon Endo-Surgery, Inc. | Medical device for providing access |
US8100887B2 (en) | 2004-03-09 | 2012-01-24 | Bluesky Medical Group Incorporated | Enclosure-based reduced pressure treatment system |
US8062272B2 (en) | 2004-05-21 | 2011-11-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
US7776028B2 (en) | 2004-04-05 | 2010-08-17 | Bluesky Medical Group Incorporated | Adjustable overlay reduced pressure wound treatment system |
US7708724B2 (en) | 2004-04-05 | 2010-05-04 | Blue Sky Medical Group Incorporated | Reduced pressure wound cupping treatment system |
US7998125B2 (en) | 2004-05-21 | 2011-08-16 | Bluesky Medical Group Incorporated | Hypobaric chamber treatment system |
WO2007142688A1 (en) | 2006-06-02 | 2007-12-13 | Bengtson Bradley P | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
US8551075B2 (en) | 2006-06-02 | 2013-10-08 | Kci Medical Resources | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
WO2007143179A2 (en) | 2006-06-02 | 2007-12-13 | Bengtson Bradley P | Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing |
CA2573256C (en) * | 2007-01-03 | 2013-08-13 | Jeffrey H. Steele | Locking mechanism for a retractable cargo bed |
WO2008103625A2 (en) * | 2007-02-21 | 2008-08-28 | C.R. Bard, Inc. | Acs therapy system |
US20090082633A1 (en) * | 2007-09-25 | 2009-03-26 | Biten Kishore Kathrani | Inflatable medical device |
US20090082634A1 (en) * | 2007-09-25 | 2009-03-26 | Biten Kishore Kathrani | Surgical method |
US20090177223A1 (en) * | 2008-01-03 | 2009-07-09 | Tara Chand Singhal | System and method for management of type 2 diabetes |
MX2011002861A (en) | 2008-09-18 | 2011-04-26 | Kci Licensing Inc | Therapy delivery systems and methods. |
CA2741446C (en) | 2008-10-29 | 2017-12-19 | Tyler Simmons | Medical canister connectors |
EP2623137B2 (en) | 2008-10-29 | 2022-06-08 | KCI Licensing, Inc. | Reduced pressure wound closure systems |
US8052624B2 (en) * | 2008-10-29 | 2011-11-08 | Stryker Corporation | Negative pressure, thermal energy transfer device that also provides positive pressure to the patient |
US8821419B1 (en) * | 2011-05-27 | 2014-09-02 | Allen L. Van Beek | Flexible interface external micro vacuum chamber tissue expander |
US9757501B2 (en) * | 2012-04-13 | 2017-09-12 | Board Of Regents, The University Of Texas System | Methods and apparatus for lowering intracranial and intraspinal cord pressure |
US10130554B2 (en) * | 2014-01-21 | 2018-11-20 | Robert George Aronson | System for therapeutic treatment by vacuum pressure and method of use thereof |
US11819334B2 (en) | 2014-03-27 | 2023-11-21 | Smart Human Dynamics, Inc. | Systems, devices, and methods for tracking abdominal orientation and activity for prevention of poor respiratory disease outcomes |
US9585614B2 (en) | 2014-03-27 | 2017-03-07 | Smart Human Dynamics, Inc. | Systems, devices, and methods for tracking abdominal orientation and activity |
US11903921B2 (en) | 2020-04-05 | 2024-02-20 | Michael Mong | Systems and methods for treating coronavirus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3062215A (en) * | 1956-01-14 | 1962-11-06 | Ockert S Heyns | Method and apparatus for facilitating the processes of parturition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US230351A (en) * | 1880-07-20 | seyberlich | ||
US726791A (en) * | 1902-08-18 | 1903-04-28 | Charles E H Armbruster | Depurator. |
US1498430A (en) * | 1920-09-27 | 1924-06-17 | Aloysius C Doerfler | Vacuum appliance |
US2597637A (en) * | 1946-09-12 | 1952-05-20 | Heidenwolf Hermann | Obstetrical apparatus |
US2490395A (en) * | 1947-03-17 | 1949-12-06 | J J Monaghan Company Inc | Respirator |
US2917050A (en) * | 1958-11-28 | 1959-12-15 | Arthur D Kenyon | Means and method for assisting the birth of a child |
CH454349A (en) * | 1967-04-12 | 1968-04-15 | Battista Malavenda Giovanni | Controlled decompression equipment to promote fetal intra-uterine life and to prepare the pregnant woman for childbirth |
DE1800287A1 (en) * | 1968-10-01 | 1970-04-23 | Walter Wobbe | Device for negative pressure treatment of pregnant women |
US4014344A (en) * | 1973-01-11 | 1977-03-29 | Moises Hernandez Gutierrez | Decompression beds for childbirth and method for using them |
US3988793A (en) * | 1975-09-16 | 1976-11-02 | Abitbol M Maurice | Device for preventing and treating toxemia in pregnant women |
-
1998
- 1998-07-24 US US09/121,600 patent/US5938626A/en not_active Expired - Fee Related
-
1999
- 1999-07-16 WO PCT/US1999/016173 patent/WO2000004835A1/en not_active Application Discontinuation
- 1999-07-16 CA CA002335013A patent/CA2335013A1/en not_active Abandoned
- 1999-07-16 AU AU52152/99A patent/AU746731B2/en not_active Ceased
- 1999-07-16 JP JP2000560830A patent/JP2002521083A/en active Pending
- 1999-07-16 EP EP99937283A patent/EP1100388A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3062215A (en) * | 1956-01-14 | 1962-11-06 | Ockert S Heyns | Method and apparatus for facilitating the processes of parturition |
Non-Patent Citations (1)
Title |
---|
SCOTT D.B. ET AL: "A Method of Abdominal Decompression in Labor", THE LANCET, 28 May 1960 (1960-05-28), pages 1181 - 1183, XP002923337 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2680006C1 (en) * | 2018-01-22 | 2019-02-14 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Method for predicting the risk of development of internal hypertension among cardiac surgery patients |
Also Published As
Publication number | Publication date |
---|---|
AU746731B2 (en) | 2002-05-02 |
US5938626A (en) | 1999-08-17 |
CA2335013A1 (en) | 2000-02-03 |
AU5215299A (en) | 2000-02-14 |
JP2002521083A (en) | 2002-07-16 |
EP1100388A1 (en) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU746731B2 (en) | Apparatus for lowering intra-abdominal pressure | |
US5893368A (en) | Method for lowering abdominal pressure | |
US6436064B1 (en) | Compression garment for selective application for treatment of lymphedema and related illnesses manifested at various locations of the body | |
US6315745B1 (en) | Compression garment for selective application for treatment of lymphedema and related illnesses manifested at various locations of the body | |
US6852089B2 (en) | Compression garment for selective application for treatment of lymphedema and related illnesses manifested at various locations of the body | |
US20050154336A1 (en) | Segmented pneumatic pad for regulating pressure upon parts of the body during usage | |
US20200054800A1 (en) | Catheter and Method for Inducing Negative Pressure in a Patient's Bladder | |
WO2018200643A1 (en) | Catheter and method for inducing negative pressure in a patient's bladder | |
JP2003534047A (en) | Semi-rigid pelvic compression splint for trauma | |
US20190174929A1 (en) | Support Bed for Pregnant Women | |
WO1997042988A2 (en) | Method and apparatus and treatment of patients by lowering intra-abdominal pressure | |
Drummond et al. | Effects of posture on limb blood flow in late pregnancy | |
Girling | Physiology of pregnancy | |
US11135048B2 (en) | Distributed pressure fenestrated urethral compression apparatus for treatment of male urinary sphincter deficiency with preservation of blood flow | |
CN212186863U (en) | Ice bag for compressing abdominal wound after caesarean section operation | |
Antypas | Management of pressure sores | |
RU2738548C1 (en) | Device preventing premature opening of uterine cervix in pregnant woman | |
RU42419U1 (en) | BONDS FOR PREOPERATIVE PREPARATION OF PATIENTS WITH LARGE VENTRAL HERNIA | |
Simkin | Penny Simkin, BA, PT, CCE, CD (DONA), Lisa Hanson, PhD, CNM, FACNM, and Ruth Ancheta, BA, MA, ICCE, CD (DONA) | |
US20080099028A1 (en) | Male Genitalia Support Device, and Method for Supporting Male Genitalia | |
Mishra et al. | Successful Management of Severe Grade Ovarian Hyperstimulation Syndrome: Case Report | |
CN115554125A (en) | Pneumatic protection device for diabetic foot ulcer and use method | |
Orisabinone et al. | Antepartum Vulva Haematoma, Surgical Intervention and Subsequent Vaginal Delivery | |
Furnari et al. | Pregnancy And Psychomotricity | |
BONICA | Basic considerations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2335013 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52152/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 560830 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999937283 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999937283 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 52152/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999937283 Country of ref document: EP |